论文部分内容阅读
目的:探讨表皮生长因子受体(EG-FR)过表达和EGFR基因扩增对胶质母细胞瘤(GBM)预后的影响。方法:以相对危险比(RH)为效应统计量,应用Meta分析方法对有关EGFR过表达和EGFR扩增与GBM预后的文献进行定量综合分析。结果:纳入的12篇文献。研究EGFR过表达的文献7篇,累计病例626例,阳性率为52.9%;研究EGFR扩增的6篇,累计病例433例,阳性率为33.5%。EGFR过表达与GBM预后关系的合并相对危险比(RH)及95%可信区间(CI)分别为1.06和0.73~1.53;EGFR扩增与GBM预后关系的合并RH及95%CI分别为1.11和0.81~1.53。结论:EGFR过表达和EGFR扩增可能均与GBM预后无关。
Objective: To investigate the effect of epidermal growth factor receptor (EGF-FR) overexpression and EGFR gene amplification on the prognosis of glioblastoma (GBM). Methods: Relative risk ratio (RH) was used as the effect statistics, Meta-analysis was used to quantitatively analyze the literature about EGFR overexpression, EGFR amplification and prognosis of GBM. Results: 12 articles included. There are 7 literatures about EGFR overexpression, with a total of 626 cases, the positive rate was 52.9%. There were 6 EGFR amplification cases in which 433 cases were positive, the positive rate was 33.5%. The combined relative risk ratio (RH) and 95% confidence interval (CI) of EGFR overexpression and GBM prognosis were 1.06 and 0.73 to 1.53, respectively. The combined RH and 95% CI of EGFR amplification and GBM prognosis were 1.11 and 0.81 ~ 1.53. Conclusion: EGFR overexpression and EGFR amplification may not be related to the prognosis of GBM.